AU2015330102B2 - Pharmaceutical formulations of PEGylated liposomes and blood coagulation factors - Google Patents

Pharmaceutical formulations of PEGylated liposomes and blood coagulation factors Download PDF

Info

Publication number
AU2015330102B2
AU2015330102B2 AU2015330102A AU2015330102A AU2015330102B2 AU 2015330102 B2 AU2015330102 B2 AU 2015330102B2 AU 2015330102 A AU2015330102 A AU 2015330102A AU 2015330102 A AU2015330102 A AU 2015330102A AU 2015330102 B2 AU2015330102 B2 AU 2015330102B2
Authority
AU
Australia
Prior art keywords
factor
blood
colloidal particle
pharmaceutical composition
amphipathic lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015330102A
Other languages
English (en)
Other versions
AU2015330102A1 (en
Inventor
William Henry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cantab Biopharmaceuticals Patents Ltd
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Publication of AU2015330102A1 publication Critical patent/AU2015330102A1/en
Application granted granted Critical
Publication of AU2015330102B2 publication Critical patent/AU2015330102B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2015330102A 2014-10-06 2015-10-06 Pharmaceutical formulations of PEGylated liposomes and blood coagulation factors Ceased AU2015330102B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1417589.7A GB201417589D0 (en) 2014-10-06 2014-10-06 Pharmaceutical Formulations
GB1417589.7 2014-10-06
PCT/EP2015/073003 WO2016055447A1 (en) 2014-10-06 2015-10-06 Pharmaceutical formulations of pegylated liposomes and blood coagulation factors

Publications (2)

Publication Number Publication Date
AU2015330102A1 AU2015330102A1 (en) 2017-05-25
AU2015330102B2 true AU2015330102B2 (en) 2021-01-28

Family

ID=51946871

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015330102A Ceased AU2015330102B2 (en) 2014-10-06 2015-10-06 Pharmaceutical formulations of PEGylated liposomes and blood coagulation factors

Country Status (16)

Country Link
US (2) US20170304203A1 (enExample)
EP (1) EP3204034B9 (enExample)
JP (3) JP2017531659A (enExample)
AU (1) AU2015330102B2 (enExample)
BR (1) BR112017007031A2 (enExample)
CA (1) CA2994891C (enExample)
ES (1) ES2954134T3 (enExample)
GB (1) GB201417589D0 (enExample)
HR (1) HRP20230985T1 (enExample)
HU (1) HUE063656T2 (enExample)
MX (1) MX384517B (enExample)
PL (1) PL3204034T3 (enExample)
RS (1) RS64461B1 (enExample)
RU (1) RU2737291C2 (enExample)
SM (1) SMT202300271T1 (enExample)
WO (1) WO2016055447A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201417589D0 (en) * 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
JP6825010B2 (ja) * 2016-05-26 2021-02-03 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ 遠心法によるリポソーム調製のための方法及び装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007002886A2 (en) * 2005-06-29 2007-01-04 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic pr0tein-lip1d complexes

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6326353B1 (en) 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
DE69418334T2 (de) 1993-08-06 2000-01-27 Opperbas Holding B.V., Amsterdam Verfahren zur hohen beladung von vesikeln mit biopolymeren substanzen
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US6156337A (en) * 1994-07-08 2000-12-05 Opperbas Holding B.V. Method for high loading of vesicles with biopolymeric substances
US6310183B1 (en) * 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
MXPA00010241A (es) * 1998-04-27 2004-09-06 Opperbas Holding Bv Composicion farmaceutica que comprende el factor viii y liposomas neutrales..
RU2250911C2 (ru) * 1999-07-14 2005-04-27 Элзэ Копэрейшн Липосомальная композиция, нейтральный липополимер и способ увеличения времени циркуляции липосомы
AU2001256148A1 (en) * 2000-05-03 2001-11-12 Novo-Nordisk A/S Subcutaneous administration of coagulation factor vii
US20030232075A1 (en) 2002-05-06 2003-12-18 University Of Minnesota, A Minnesota Corporation Compositions for producing factor Xa
DE602004013769D1 (de) 2003-04-15 2008-06-26 Opperbas Holding Bv Pharmazeutische zusammensetzung, enthaltend proteine und/oder polypeptide sowie kolloidpartikel
EP2099475B1 (en) * 2007-01-03 2016-08-24 Novo Nordisk Health Care AG Subcutaneous administration of coagulation factor viia-related polypeptides
CA2701884A1 (en) 2007-10-15 2009-04-23 Wake Forest University Health Sciences Methods and compositions for printing biologically compatible nanotube composites of autologous tissue
AU2010255391C1 (en) 2009-06-03 2016-10-27 Sequessome Technology Holdings Limited Formulations for the treatment of deep tissue pain
MX336482B (es) 2009-08-21 2016-01-21 Henk-Andre Kroon Formulaciones vesiculares.
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
TW201240664A (en) * 2010-09-01 2012-10-16 Portola Pharm Inc Methods and formulations of treating thrombosis with betrixaban and a P-glycoprotein inhibitor
EP2838566A2 (en) * 2012-04-16 2015-02-25 Cantab Biopharmaceuticals Patents Limited Optimised subcutaneous therapeutic agents
GB201417589D0 (en) * 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007002886A2 (en) * 2005-06-29 2007-01-04 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic pr0tein-lip1d complexes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BARU M. ET AL., THROMBOSIS AND HAEMOSTASIS, (2005-06-01), vol. 93, no. 6, pages 1061 - 1068 *

Also Published As

Publication number Publication date
HUE063656T2 (hu) 2024-01-28
JP7573582B2 (ja) 2024-10-25
JP2023002687A (ja) 2023-01-10
AU2015330102A1 (en) 2017-05-25
RS64461B1 (sr) 2023-09-29
EP3204034A1 (en) 2017-08-16
CA2994891A1 (en) 2016-04-14
CA2994891C (en) 2023-04-04
US20170304203A1 (en) 2017-10-26
JP2017531659A (ja) 2017-10-26
HRP20230985T1 (hr) 2023-12-08
WO2016055447A1 (en) 2016-04-14
EP3204034B9 (en) 2023-10-04
EP3204034C0 (en) 2023-06-07
US11484499B2 (en) 2022-11-01
RU2017115831A3 (enExample) 2019-05-06
RU2017115831A (ru) 2018-11-14
US20190060235A1 (en) 2019-02-28
MX384517B (es) 2025-03-14
EP3204034B1 (en) 2023-06-07
SMT202300271T1 (it) 2023-09-06
ES2954134T3 (es) 2023-11-20
GB201417589D0 (en) 2014-11-19
MX2017004378A (es) 2018-02-09
JP2020183446A (ja) 2020-11-12
PL3204034T3 (pl) 2023-11-06
BR112017007031A2 (pt) 2018-01-30
RU2737291C2 (ru) 2020-11-26

Similar Documents

Publication Publication Date Title
US20250170244A1 (en) Colloidal particles for use in medicine
JP7573582B2 (ja) Ｐｅｇ化リポソームおよび血液凝固因子の製剤処方
US20240366732A1 (en) Modified colloidal particles for use in the treatment of haemophilia a
WO2017064289A1 (en) Colloidal particles for topical administration with therapeutic agent
WO2017064300A1 (en) Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
US20240358801A1 (en) Modified colloidal particles for use in the treatment of haemophilia a
US20250064738A1 (en) Modified colloidal particles for use in the treatment of haemophilia a

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired